 WOBURN, Mass., Feb. 11, 2022 GLOBE NEWSWIRE -- Replimune Group, Inc. NASDAQ: REPL, a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference being held virtually on Friday, February 18, 2022 at 8:40 AM ET. 